臺灣博碩士論文加值系統

肺癌目前在台灣及全球，高居所有癌症死因的第一位，且至少有8成以上是屬於非小細胞肺癌。非小細胞肺癌在組織學上又可細分為腺癌、鱗狀細胞癌及大細胞癌等，並以腺癌最為常見。腫瘤轉移是肺癌的致死主因，癌細胞會經由上皮-間質型態的相互轉換，得以侵襲、擴散而造成患者預後不佳。覆盆子是一種薔薇科懸鉤子屬的木本植物，富含多酚（polyphenol）物質，已被證實具有抗氧化、抗菌及抗發炎等生物活性，且有助於癌症的預防及治療，但其抗癌的詳細作用機轉仍不明瞭。因此本篇研究是以人類肺腺癌細胞株A549為實驗對象，探討覆盆子乙酸乙酯萃取物（RIEE）抑制A549細胞侵襲的作用機制，並進行裸鼠異種移植的體內試驗來檢測RIEE的抗腫瘤效果。先前我們實驗室已知RIEE會抑制PI3K/Akt訊號路徑、蛋白酶活性、snail-1及細胞骨架蛋白表現。本篇進一步利用PI3K抑制劑LY294002、snail-1 siRNA與RIEE處理A549細胞，依序進行invasion assay、gelatin zymography、casein zymography、western blot analysis及immunofluorescence staining等實驗，結果證實RIEE能夠抑制A549細胞的侵襲能力，也許可經由兩種作用機制：（1）抑制PI3K/Akt訊號路徑，減少NF-κB的蛋白表現，而降低MMP-2及u-PA的活性。（2）抑制PI3K/Akt訊號路徑，減少NF-κB的蛋白表現，而抑制snail-1並增加E-cadherin的表現。另外在A549細胞移植裸鼠的體內實驗，也證實RIEE可抑制腫瘤的生長。綜上所述，覆盆子乙酸乙酯的萃取物可能具有開發成為抗腫瘤轉移及治療肺癌藥物的潛力。

Lung cancer is the leading cause of cancer mortality in Taiwan and worldwide. At least 80% of lung cancer is non-small cell lung cancer (NSCLC) which is further divided histologically into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Adenocarcinoma is the most common type of lung cancer. Metastases are the main cause of death from lung cancer. Carcinoma cells undergo epithelial-mesenchymal transition (EMT) to invade and disseminate from the primary tumor, leading to poor prognosis in lung cancer patients. Rubus idaeus L. is a woody plant belonging to the Rosaceae family, genus Rubus. The plant is rich in polyphenols with reported biological activities such as antioxidant, antimicrobial, and anti-inflammatory properties, which are beneficial in cancer prevention and treatment, but the detailed mechanisms underlying the anticancer effects of Rubus idaeus remain unclear. In this study, human lung adenocarcinoma epithelial cell line, A549 was used not only to investigate the mechanisms of action of ethyl acetate extract from Rubus idaeus (RIEE) on the invasion of A549 cells, but to explore the anti-tumor effects in a nude mice xenograft model. Our previous study showed that RIEE could inhibit the PI3K/Akt signaling pathway, the activities of proteases, and the expression of snail and cytoskeletal proteins. Here, we further performed a series of assays for cell invasion, gelatin zymography, casein zymography, western blot and immunofluorescence, using A549 cells treated with the PI3K/Akt inhibitor LY294002, snail-1 siRNA and RIEE. Our data demonstrates that RIEE may inhibit A549 cells invasion through two mechanisms: (1) inhibition of the PI3K/Akt pathway and NF-κB expression to suppress the activities of MMP-2 and uPA, and (2) inhibition of the PI3K/Akt pathway and NF-κB expression to up-regulation E-cadherin via inhibition of snail-1. In addition, we show that RIEE could inhibit tumor cell growth in an A549 xenograft model. Collectively, RIEE may have a potential to develope as anti-metastatic and cancer therapeutic drug for lung cancer.

目錄…………………………………………………………………… I
中英文摘要……………………………………………………………II
縮寫表………………………………………………………………… V
壹、 緒論………………………………………………………… 1
貳、 研究動機……………………………………………………19
參、 實驗材料與方法……………………………………………20
肆、 實驗結果……………………………………………………32
伍、 討論…………………………………………………………36
陸、 參考文獻……………………………………………………41
柒、 圖表與圖表說明……………………………………………52

Agarwal, A., Das, K., Lerner, N., Sathe, S., Cicek, M., Casey, G., and Sizemore, N. (2004). The AKT//I[kappa]B kinase pathway promotes angiogenic//metastatic gene expression in colorectal cancer by activating nuclear factor-[kappa]B and [beta]-catenin. Oncogene 24, 1021-1031.
Andreasen, P. A., Kjoller, L., Christensen, L., and Duffy, M. J. (1997). The urokinase-type plasminogen activator system in cancer metastasis: a review. International journal of cancer Journal international du cancer 72, 1-22.
Bauvois, B. (2012). New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochimica et biophysica acta 1825, 29-36.
Berx, G., and Roy, F. V. (2001). The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Research : BCR 3, 289-293.
Berx, G., Staes, K., van Hengel, J., Molemans, F., Bussemakers, M. J., van Bokhoven, A., and van Roy, F. (1995). Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics 26, 281-289.
Biesalski, H. K., Bueno de Mesquita, B., Chesson, A., Chytil, F., Grimble, R., Hermus, R. J., Kohrle, J., Lotan, R., Norpoth, K., Pastorino, U., and Thurnham, D. (1998). European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel. CA: a cancer journal for clinicians 48, 167-176; discussion 164-166.
Blanco, M. J., Moreno-Bueno, G., Sarrio, D., Locascio, A., Cano, A., Palacios, J., and Nieto, M. A. (2002). Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 21, 3241-3246.
Blasi, F., and Carmeliet, P. (2002). uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3, 932-943.
Boivin, D., Blanchette, M., Barrette, S., Moghrabi, A., and Beliveau, R. (2007). Inhibition of cancer cell proliferation and suppression of TNF-induced activation of NFkappaB by edible berry juice. Anticancer research 27, 937-948.
Brew, K., Dinakarpandian, D., and Nagase, H. (2000). Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochimica et biophysica acta 1477, 267-283.
Brownson, R. C., Alavanja, M. C., Caporaso, N., Simoes, E. J., and Chang, J. C. (1998). Epidemiology and prevention of lung cancer in nonsmokers. Epidemiologic reviews 20, 218-236.
Cano, A., Perez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., Portillo, F., and Nieto, M. A. (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nature cell biology 2, 76-83.
Castellano, E., and Downward, J. (2011). RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes & Cancer 2, 261-274.
Castellino, F. J., and Ploplis, V. A. (2005). Structure and function of the plasminogen/plasmin system. Thrombosis and haemostasis 93, 647-654.
Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A., and McCubrey, J. A. (2003). Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17, 590-603.
Choi, K. Y., Swierczewska, M., Lee, S., and Chen, X. (2012). Protease-Activated Drug Development. Theranostics 2, 156-178.
Collen, D., and Lijnen, H. R. (1991). Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78, 3114-3124.
Collen, D., and Lijnen, H. R. (2005). Thrombolytic agents. Thrombosis and haemostasis 93, 627-630.
Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven, L., Bruyneel, E., Mareel, M., Huylebroeck, D., and van Roy, F. (2001). The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Molecular cell 7, 1267-1278.
Corbel, M., Boichot, E., and Lagente, V. (2000). Role of gelatinases MMP-2 and MMP-9 in tissue remodeling following acute lung injury. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica [et al] 33, 749-754.
Daniele, A., Zito, A. F., Giannelli, G., Divella, R., Asselti, M., Mazzocca, A., Paradiso, A., and Quaranta, M. (2010). Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer research 30, 3521-3527.
Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. (1985). Plasminogen activators, tissue degradation, and cancer. Advances in cancer research 44, 139-266.
Dano, K., Behrendt, N., Hoyer-Hansen, G., Johnsen, M., Lund, L. R., Ploug, M., and Romer, J. (2005). Plasminogen activation and cancer. Thrombosis and haemostasis 93, 676-681.
Dass, K., Ahmad, A., Azmi, A. S., Sarkar, S. H., and Sarkar, F. H. (2008). Evolving role of uPA/uPAR system in human cancers. Cancer treatment reviews 34, 122-136.
Dolcet, X., Llobet, D., Pallares, J., and Matias-Guiu, X. (2005). NF-kB in development and progression of human cancer. Virchows Archiv : an international journal of pathology 446, 475-482.
Duffy, M. J., Maguire, T. M., McDermott, E. W., and O''Higgins, N. (1999). Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. Journal of surgical oncology 71, 130-135.
Durgo, K., Belscak-Cvitanovic, A., Stancic, A., Franekic, J., and Komes, D. (2012). The bioactive potential of red raspberry (Rubus idaeus L.) leaves in exhibiting cytotoxic and cytoprotective activity on human laryngeal carcinoma and colon adenocarcinoma. Journal of medicinal food 15, 258-268.
Engelman, J. A. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature reviews Cancer 9, 550-562.
Engelman, J. A., Luo, J., and Cantley, L. C. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature reviews Genetics 7, 606-619.
Fan, S. Q., Wei, Q. Y., Li, M. R., Zhang, L. Q., and Liang, Q. C. (2003). [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma]. Ai zheng = Aizheng = Chinese journal of cancer 22, 968-973.
Feng, R., Ni, H. M., Wang, S. Y., Tourkova, I. L., Shurin, M. R., Harada, H., and Yin, X. M. (2007). Cyanidin-3-rutinoside, a natural polyphenol antioxidant, selectively kills leukemic cells by induction of oxidative stress. The Journal of biological chemistry 282, 13468-13476.
Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the ''seed and soil'' hypothesis revisited. Nature reviews Cancer 3, 453-458.
Franke, T. F. (2008). PI3K/Akt: getting it right matters. Oncogene 27, 6473-6488.
Fresno Vara, J. A., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., and Gonzalez-Baron, M. (2004). PI3K/Akt signalling pathway and cancer. Cancer treatment reviews 30, 193-204.
Gao, T., Furnari, F., and Newton, A. C. (2005). PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Molecular cell 18, 13-24.
García-Pardo, A., and Opdenakker, G. (2015). Nonproteolytic functions of matrix metalloproteinases in pathology and insights for the development of novel therapeutic inhibitors. Metalloproteinases In Medicine 2, 19.
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., and Stein, H. (1984). Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. Journal of immunology (Baltimore, Md : 1950) 133, 1710-1715.
Gilmore, T. D. (2006). Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25, 6680-6684.
Guilford, P., Hopkins, J., Harraway, J., McLeod, M., McLeod, N., Harawira, P., Taite, H., Scoular, R., Miller, A., and Reeve, A. E. (1998). E-cadherin germline mutations in familial gastric cancer. Nature 392, 402-405.
Gupta, G. P., and Massague, J. (2006). Cancer metastasis: building a framework. Cell 127, 679-695.
Guruvayoorappan, C., and Kuttan, G. (2008). Amentoflavone inhibits experimental tumor metastasis through a regulatory mechanism involving MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, VEGF, ERK-1, ERK-2, STAT-1, NM23 and cytokines in lung tissues of C57BL/6 mice. Immunopharmacology and immunotoxicology 30, 711-727.
Hajra, K. M., Chen, D. Y., and Fearon, E. R. (2002). The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer research 62, 1613-1618.
Hanada, M., Feng, J., and Hemmings, B. A. (2004). Structure, regulation and function of PKB/AKT--a major therapeutic target. Biochimica et biophysica acta 1697, 3-16.
Hayat, M. J., Howlader, N., Reichman, M. E., and Edwards, B. K. (2007). Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. The oncologist 12, 20-37.
Hemmings, B. A., and Restuccia, D. F. (2012). PI3K-PKB/Akt pathway. Cold Spring Harbor perspectives in biology 4, a011189.
Hirohashi, S. (1998). Inactivation of the E-Cadherin-Mediated Cell Adhesion System in Human Cancers. The American Journal of Pathology 153, 333-339.
Hoylaerts, M., Rijken, D. C., Lijnen, H. R., and Collen, D. (1982). Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. The Journal of biological chemistry 257, 2912-2919.
Hu, J., Van den Steen, P. E., Sang, Q. X., and Opdenakker, G. (2007). Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6, 480-498.
Huber, M. A., Azoitei, N., Baumann, B., Grunert, S., Sommer, A., Pehamberger, H., Kraut, N., Beug, H., and Wirth, T. (2004). NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114, 569-581.
Hummer, K. E. (2010). Rubus pharmacology: antiquity to the present. HortScience 45, 1587-1591.
Hung, J. J., Yeh, Y. C., Jeng, W. J., Wu, K. J., Huang, B. S., Wu, Y. C., Chou, T. Y., and Hsu, W. H. (2014). Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32, 2357-2364.
Hwang, E. S., and Lee, H. J. (2008). Benzyl isothiocyanate inhibits metalloproteinase-2/-9 expression by suppressing the mitogen-activated protein kinase in SK-Hep1 human hepatoma cells. Food Chem Toxicol 46, 2358-2364.
Jamora, C., and Fuchs, E. (2002). Intercellular adhesion, signalling and the cytoskeleton. Nature cell biology 4, E101-108.
Jia, W., Gao, W., and Tang, L. (2003). Antidiabetic herbal drugs officially approved in China. Phytotherapy research : PTR 17, 1127-1134.
Julien, S., Puig, I., Caretti, E., Bonaventure, J., Nelles, L., van Roy, F., Dargemont, C., de Herreros, A. G., Bellacosa, A., and Larue, L. (2007). Activation of NF-[kappa]B by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 26, 7445-7456.
Kalluri, R., and Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation 119, 1420-1428.
Karin, M., Cao, Y., Greten, F. R., and Li, Z. W. (2002). NF-kappaB in cancer: from innocent bystander to major culprit. Nature reviews Cancer 2, 301-310.
Karroum, A., Mirshahi, P., Benabbou, N., Faussat, A. M., Soria, J., Therwath, A., Mirshahi, M., and Hatmi, M. (2010). Matrix metalloproteinase-9 is required for tubular network formation and migration of resistant breast cancer cells MCF-7 through PKC and ERK1/2 signalling pathways. Cancer letters 295, 242-251.
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., and Waterfield, M. D. (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annual review of cell and developmental biology 17, 615-675.
Kwaan, H. C., and McMahon, B. (2009). The role of plasminogen-plasmin system in cancer. Cancer treatment and research 148, 43-66.
López-Otín, C., and Matrisian, L. M. (2007). Emerging roles of proteases in tumour suppression. Nature reviews Cancer 7, 800-808.
Lamouille, S., Xu, J., and Derynck, R. (2014). Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15, 178-196.
Larue, L., and Bellacosa, A. (2005). Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3'' kinase/AKT pathways. Oncogene 24, 7443-7454.
Lee, H. S., Lee, H. K., Kim, H. S., Yang, H. K., and Kim, W. H. (2003). Tumour suppressor gene expression correlates with gastric cancer prognosis. The Journal of pathology 200, 39-46.
Li, X., and Wang, H. (2005). Chinese herbal medicine in the treatment of chronic kidney disease. Advances in chronic kidney disease 12, 276-281.
Liang, H., Xue, C., Zhou, D., and Li, C. (2003). Chinese herbal medicine for lung cancer: a critical literature review. Chinese Journal of Integrative Medicine 9, 157-160.
Lijnen, H. R. (2001). Elements of the fibrinolytic system. Annals of the New York Academy of Sciences 936, 226-236.
Lijnen, H. R., and Collen, D. (1995). Mechanisms of physiological fibrinolysis. Bailliere''s clinical haematology 8, 277-290.
Lin, C. Y., Tsai, P. H., Kandaswami, C. C., Chang, G. D., Cheng, C. H., Huang, C. J., Lee, P. P., Hwang, J. J., and Lee, M. T. (2011). Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells. Molecular cancer 10, 87.
Lindstrom, T. M., and Bennett, P. R. (2005). The role of nuclear factor kappa B in human labour. Reproduction (Cambridge, England) 130, 569-581.
Liu, P., Cheng, H., Roberts, T. M., and Zhao, J. J. (2009). Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer. Nature reviews Drug discovery 8, 627-644.
Maira, S. M., Galetic, I., Brazil, D. P., Kaech, S., Ingley, E., Thelen, M., and Hemmings, B. A. (2001). Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science (New York, NY) 294, 374-380.
Min, K. W., Kim, D. H., Do, S. I., Kim, K., Lee, H. J., Chae, S. W., Sohn, J. H., Pyo, J. S., Oh, Y. H., Kim, W. S., et al. (2014). Expression patterns of stromal MMP-2 and tumoural MMP-2 and -9 are significant prognostic factors in invasive ductal carcinoma of the breast. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 122, 1196-1206.
Miyake, H., Muramaki, M., Kurahashi, T., Takenaka, A., and Fujisawa, M. (2010). Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urologic oncology 28, 145-151.
Mohammed, F., Smookler, D., and Khokha, R. (2003). Metalloproteinases, inflammation, and rheumatoid arthritis. Annals of the Rheumatic Diseases 62, ii43-ii47.
Moroz, A., Delella, F. K., Almeida, R., Lacorte, L. M., Favaro, W. J., Deffune, E., and Felisbino, S. L. (2013). Finasteride inhibits human prostate cancer cell invasion through MMP2 and MMP9 downregulation. PloS one 8, e84757.
Moustakas, A., and Heldin, C. H. (2007). Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer science 98, 1512-1520.
Nagase, H. (1998). Cell surface activation of progelatinase A (proMMP-2) and cell migration. Cell Res 8, 179-186.
Nagase, H., and Woessner, J. F., Jr. (1999). Matrix metalloproteinases. The Journal of biological chemistry 274, 21491-21494.
Nieto, M. A. (2002). The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 3, 155-166.
Oeckinghaus, A., and Ghosh, S. (2009). The NF-κB Family of Transcription Factors and Its Regulation. Cold Spring Harbor perspectives in biology 1, a000034.
Okada, N., Ishida, H., Murata, N., Hashimoto, D., Seyama, Y., and Kubota, S. (2001). Matrix metalloproteinase-2 and -9 in bile as a marker of liver metastasis in colorectal cancer. Biochemical and biophysical research communications 288, 212-216.
Osaki, M., Oshimura, M., and Ito, H. (2004). PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis : an international journal on programmed cell death 9, 667-676.
Overall, C. M., and Lopez-Otin, C. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature reviews Cancer 2, 657-672.
Papazafiropoulou, A., and Tentolouris, N. (2009). Matrix metalloproteinases and cardiovascular diseases. Hippokratia 13, 76-82.
Parker, C., Rampaul, R. S., Pinder, S. E., Bell, J. A., Wencyk, P. M., Blamey, R. W., Nicholson, R. I., and Robertson, J. F. R. (2001). E-cadherin as a prognostic indicator in primary breast cancer. British Journal of Cancer 85, 1958-1963.
Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA: a cancer journal for clinicians 55, 74-108.
Pfister, C., Lacombe, L., Vezina, M. C., Moore, L., Larue, H., Tetu, B., Meyer, F., and Fradet, Y. (1999). Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors. Human pathology 30, 1350-1355.
Philip, S., Bulbule, A., and Kundu, G. C. (2001). Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. The Journal of biological chemistry 276, 44926-44935.
Ra, H.-J., and Parks, W. C. (2007). Control of Matrix Metalloproteinase Catalytic Activity. Matrix biology : journal of the International Society for Matrix Biology 26, 587-596.
Raz, D. J., He, B., Rosell, R., and Jablons, D. M. (2006). Bronchioloalveolar carcinoma: a review. Clinical lung cancer 7, 313-322.
Rodrigo, K. A., Rawal, Y., Renner, R. J., Schwartz, S. J., Tian, Q., Larsen, P. E., and Mallery, S. R. (2006). Suppression of the Tumorigenic Phenotype in Human Oral Squamous Cell Carcinoma Cells by an Ethanol Extract Derived From Freeze-Dried Black Raspberries. Nutrition and cancer 54, 58-68.
Ross, H. A., McDougall, G. J., and Stewart, D. (2007). Antiproliferative activity is predominantly associated with ellagitannins in raspberry extracts. Phytochemistry 68, 218-228.
Sang, Q. X. A. (1998). Complex role of matrix metalloproteinases in angiogenesis. Cell Res 8, 171-177.
Scheel, C., and Weinberg, R. A. (2012). Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Seminars in cancer biology 22, 396-403.
Scholzen, T., and Gerdes, J. (2000). The Ki-67 protein: from the known and the unknown. Journal of cellular physiology 182, 311-322.
Seeram, N. P. (2008). Berry fruits for cancer prevention: current status and future prospects. J Agric Food Chem 56, 630-635.
Seeram, N. P., Adams, L. S., Zhang, Y., Lee, R., Sand, D., Scheuller, H. S., and Heber, D. (2006). Blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry extracts inhibit growth and stimulate apoptosis of human cancer cells in vitro. J Agric Food Chem 54, 9329-9339.
Shah, F. D., Shukla, S. N., Shah, P. M., Shukla, H. K., and Patel, P. S. (2009). Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian journal of cancer 46, 194-202.
Sharrard, R. M., and Maitland, N. J. (2007). Regulation of protein kinase B activity by PTEN and SHIP2 in human prostate-derived cell lines. Cellular signalling 19, 129-138.
Shibue, T., and Weinberg, R. A. (2011). Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Seminars in cancer biology 21, 99-106.
Sleeman, J., and Steeg, P. S. (2010). Cancer metastasis as a therapeutic target. European journal of cancer (Oxford, England : 1990) 46, 1177-1180.
Sliva, D. (2004). Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Current cancer drug targets 4, 327-336.
Smith, H. W., and Marshall, C. J. (2010). Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11, 23-36.
Sobin LH, G. M., Wittekind Ch (2009). TNM Classification of Malignant Tumours, 7th Edition. Hoboken, NJ : Wiley-Blackwell.
Springman, E. B., Angleton, E. L., Birkedal-Hansen, H., and Van Wart, H. E. (1990). Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proceedings of the National Academy of Sciences of the United States of America 87, 364-368.
Stetler-Stevenson, W. G. (1990). Type IV collagenases in tumor invasion and metastasis. Cancer metastasis reviews 9, 289-303.
Stetler-Stevenson, W. G., Liotta, L. A., and Kleiner, D. E., Jr. (1993). Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 7, 1434-1441.
Stetler-Stevenson, W. G., and Seo, D. W. (2005). TIMP-2: an endogenous inhibitor of angiogenesis. Trends in molecular medicine 11, 97-103.
Surh, Y.-J. (2004). Transcription Factors in the Cellular Signaling Network as Prime Targets of Chemopreventive Phytochemicals. Cancer Research and Treatment : Official Journal of Korean Cancer Association 36, 275-286.
Tawfik, K., Kimler, B. F., Davis, M. K., Fan, F., and Tawfik, O. (2013). Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant. Human pathology 44, 39-46.
Thanos, D., and Maniatis, T. (1995). NF-kappa B: a lesson in family values. Cell 80, 529-532.
Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nature reviews Cancer 2, 442-454.
Thiery, J. P. (2003). Epithelial-mesenchymal transitions in development and pathologies. Current opinion in cell biology 15, 740-746.
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global cancer statistics, 2012. CA: a cancer journal for clinicians 65, 87-108.
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., et al. (2015). The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 10, 1243-1260.
Tsai, J. H., and Yang, J. (2013). Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes & development 27, 2192-2206.
Vanhaesebroeck, B., Leevers, S. J., Panayotou, G., and Waterfield, M. D. (1997). Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends in biochemical sciences 22, 267-272.
Vassalli, J. D., Sappino, A. P., and Belin, D. (1991). The plasminogen activator/plasmin system. Journal of Clinical Investigation 88, 1067-1072.
Veronese, S. M., Gambacorta, M., Gottardi, O., Scanzi, F., Ferrari, M., and Lampertico, P. (1993). Proliferation index as a prognostic marker in breast cancer. Cancer 71, 3926-3931.
Vivanco, I., and Sawyers, C. L. (2002). The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nature reviews Cancer 2, 489-501.
Vleminckx, K., Vakaet, L., Jr., Mareel, M., Fiers, W., and van Roy, F. (1991). Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66, 107-119.
Vu, T. H., and Werb, Z. (2000). Matrix metalloproteinases: effectors of development and normal physiology. Genes & development 14, 2123-2133.
Wang, L. S., Hecht, S. S., Carmella, S. G., Yu, N., Larue, B., Henry, C., McIntyre, C., Rocha, C., Lechner, J. F., and Stoner, G. D. (2009). Anthocyanins in black raspberries prevent esophageal tumors in rats. Cancer prevention research (Philadelphia, Pa) 2, 84-93.
Woessner, J. F., Jr. (1991). Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 5, 2145-2154.
Xie, Z., Singh, M., and Singh, K. (2004). Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1beta. The Journal of biological chemistry 279, 39513-39519.
Xu, P., Wang, Y., Piao, Y., Bai, S., Xiao, Z., Jia, Y., Luo, S., and Zhuang, L. (2001). Effects of matrix proteins on the expression of matrix metalloproteinase-2, -9, and -14 and tissue inhibitors of metalloproteinases in human cytotrophoblast cells during the first trimester. Biology of reproduction 65, 240-246.
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., and Weinberg, R. A. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939.
Yilmaz, M., Christofori, G., and Lehembre, F. (2007). Distinct mechanisms of tumor invasion and metastasis. Trends in molecular medicine 13, 535-541.
Yin, S.-Y., Wei, W.-C., Jian, F.-Y., and Yang, N.-S. (2013). Therapeutic Applications of Herbal Medicines for Cancer Patients. Evidence-Based Complementary and Alternative Medicine 2013, 15.
Yokoyama, K., Kamata, N., Hayashi, E., Hoteiya, T., Ueda, N., Fujimoto, R., and Nagayama, M. (2001). Reverse correlation of E-cadherin and snail expression in oral squamous cell carcinoma cells in vitro. Oral oncology 37, 65-71.
Yuan, T. L., and Cantley, L. C. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-5510.
Zhang, L., Shi, J., Feng, J., Klocker, H., Lee, C., and Zhang, J. (2004). Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate cancer and prostatic diseases 7, 327-332.
Zhang, Y., Zhang, Z., Yang, Y., Wang, Y., Zu, X., and Guan, D. (2011). Diuretic Activity of Methanol Extracts of Rubus idaeus L. International Journal of Biology 3, 75.
Zheng, H., and Kang, Y. (2014). Multilayer control of the EMT master regulators. Oncogene 33, 1755-1763.
江建成 (2012) 覆盆子乙酸乙酯萃取物抑制人類肺癌細胞之上皮間質轉化及細胞侵襲和蛋白質活化作用, 中山醫學大學.
衛生福利部 (2015). 民國103年死因統計結果分析.
衛生福利部國民健康署 (2015). 101年癌症登記報告.